BIO RAD LABS INC's ticker is BIO and the CUSIP is 090572207. A total of 493 filers reported holding BIO RAD LABS INC in Q2 2022. The put-call ratio across all filers is 2.91 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEDBUSH SECURITIES INC | 1,801 | $891,000 | 0.05% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 3,414 | $1,690,000 | 0.05% |
| Private Capital Group, LLC | 126 | $62,000 | 0.05% |
| Invesco Ltd. | 316,692 | $156,763,000 | 0.05% |
| Redpoint Investment Management Pty Ltd | 810 | $401,000 | 0.05% |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 34,073 | $16,866,000 | 0.05% |
| ADVISOR PARTNERS LLC | 1,254 | $621,000 | 0.04% |
| BTR CAPITAL MANAGEMENT INC | 595 | $295,000 | 0.04% |
| Achmea Investment Management B.V. | 2,584 | $1,279,000 | 0.04% |
| Virtue Capital Management, LLC | 532 | $263,000 | 0.04% |
| Ethic Inc. | 1,177 | $583,000 | 0.04% |
| AIGEN INVESTMENT MANAGEMENT, LP | 476 | $236,000 | 0.04% |
| Qube Research & Technologies Ltd | 10,881 | $5,386,000 | 0.04% |
| PUTNAM INVESTMENTS LLC | 44,807 | $22,179,000 | 0.04% |
| Inspire Investing, LLC | 616 | $305,000 | 0.04% |
| EXCHANGE TRADED CONCEPTS, LLC | 2,801 | $1,386,000 | 0.04% |
| Man Group plc | 18,438 | $9,127,000 | 0.04% |
| ZEKE CAPITAL ADVISORS, LLC | 1,157 | $573,000 | 0.04% |
| Symmetry Partners, LLC | 1,115 | $552,000 | 0.04% |
| Dakota Wealth Management | 790 | $391,000 | 0.04% |
About BIO RAD LABS INC
Bio-Rad Laboratories, Inc. is a multinational company that specializes in the development and production of life science research and clinical diagnostic products. The company was founded in 1952 and is headquartered in Hercules, California. Bio-Rad has a global presence, with operations in more than 100 countries.
Bio-Rad's life science research products include instruments, reagents, and software used in genomics, proteomics, and cell biology research. The company's clinical diagnostic products include blood typing reagents, quality control products, and infectious disease testing kits.
Bio-Rad has a strong reputation for innovation and quality. The company has received numerous awards for its products, including the Frost & Sullivan Product Line Strategy Leadership Award in 2019 for its Droplet Digital PCR technology.
Bio-Rad's leadership team includes CEO Norman Schwartz, COO Andrew Last, and Chairman of the Board Ronald Hutton. The company has a strong financial position, with a market capitalization of over $16 billion as of August 2021.
Investors interested in Bio-Rad should keep an eye on the company's financial performance, including its revenue growth and profitability. Bio-Rad's strong reputation and innovative products make it a company to watch in the life science research and clinical diagnostic markets.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO RAD LABS INC's shareholders in Q2 2022. To view BIO RAD LABS INC's shareholder history, click here.